君實生物-B(01877.HK)擬分別向蘇州眾合及蘇州君盟增資5000萬元及1億元
格隆匯11月21日丨君實生物-B(01877.HK)發佈公告,公司擬將全資子公司蘇州眾合生物醫藥科技有限公司註冊資本增加到人民幣7.5億元,即蘇州眾合新增註冊資本人民幣5000萬元,其中公司認繳出資人民幣5000萬元;擬將全資子公司蘇州君盟生物醫藥科技有限公司註冊資本增加到人民幣6億元,即蘇州君盟新增註冊資本人民幣1億元,其中公司認繳出資人民幣1億元。
據悉,蘇州眾合生物醫藥科技有限公司經營範圍為原料藥、新藥研發及相關技術開發、技術諮詢、技術轉讓和技術服務;醫藥中間體(除藥品、化學危險品)的研發、銷售及相關技術開發、技術諮詢、技術轉讓和技術服務;單克隆抗體注射液的生產及銷售;自營和代理各類商品及技術的進出口業務。
蘇州君盟生物醫藥科技有限公司經營範圍為生物醫藥的研發並提供相關的技術諮詢、技術轉讓、技術服務;自營和代理各類商品及技術的進出口業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.